These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 11965920)

  • 21. FDA notifications. FDA approves new dosing for Kaletra.
    AIDS Alert; 2010 Jun; 25(6):70-1. PubMed ID: 20623833
    [No Abstract]   [Full Text] [Related]  

  • 22. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once-daily dosing of lopinavir/ritonavir (Kaletra) receives FDA approval.
    AIDS Patient Care STDS; 2010 Jun; 24(6):395. PubMed ID: 20575157
    [No Abstract]   [Full Text] [Related]  

  • 24. New anti-HIV drugs in development.
    Proj Inf Perspect; 1999 Sep; (28):4-8. PubMed ID: 11367365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA notifications. Generic lopinavir/ritonavir approved by FDA.
    AIDS Alert; 2009 May; 24(5):59. PubMed ID: 19452652
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
    McRae M; Clay PG; Anderson PL; Glaros AG
    Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.
    Wire MB; Ballow CH; Borland J; Shelton MJ; Lou Y; Yuen G; Lin J; Lewis EW
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2982-4. PubMed ID: 17517848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA approves new PI.
    Gadd C
    IAPAC Mon; 2006 Jun; 12(6):174. PubMed ID: 17233103
    [No Abstract]   [Full Text] [Related]  

  • 29. [No resistance even after 1 year. New drug combination against HIV].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():108. PubMed ID: 11373766
    [No Abstract]   [Full Text] [Related]  

  • 30. FDA approves darunavir.
    AIDS Patient Care STDS; 2008 Dec; 22(12):1021-2. PubMed ID: 19097261
    [No Abstract]   [Full Text] [Related]  

  • 31. FDA notifications. FDA OKs new pediatric dosing for darunavir.
    AIDS Alert; 2009 Feb; 24(2):22-4. PubMed ID: 19222149
    [No Abstract]   [Full Text] [Related]  

  • 32. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
    Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Searching for the right dose of ritonavir-saquinavir.
    TreatmentUpdate; 2001 Sep; 13(5):3. PubMed ID: 11768860
    [No Abstract]   [Full Text] [Related]  

  • 34. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.
    Taburet AM; Raguin G; Le Tiec C; Droz C; Barrail A; Vincent I; Morand-Joubert L; Chêne G; Clavel F; Girard PM
    Clin Pharmacol Ther; 2004 Apr; 75(4):310-23. PubMed ID: 15060509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Norvir capsule approved.
    AIDS Patient Care STDS; 1999 Sep; 13(9):567. PubMed ID: 10813038
    [No Abstract]   [Full Text] [Related]  

  • 36. [Overcoming weaknesses in therapy. Protease inhibitors with high IQ].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():96-7. PubMed ID: 11373795
    [No Abstract]   [Full Text] [Related]  

  • 37. Ritonavir/indinavir combination study shows promising dosing results.
    AIDS Patient Care STDS; 1998 Feb; 12(2):146-7. PubMed ID: 11361915
    [No Abstract]   [Full Text] [Related]  

  • 38. Amprenavir approved.
    STEP Perspect; 1999; 99(2):8. PubMed ID: 11366753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA approves tipranavir.
    IAPAC Mon; 2005 Jul; 11(7):190. PubMed ID: 16676422
    [No Abstract]   [Full Text] [Related]  

  • 40. Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.
    Kurowski M; Walli RK; Breske A; Kruse G; Stocker H; Banik N; Richter H; Mazur D
    AIDS; 2007 Jun; 21(10):1368-70. PubMed ID: 17545717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.